The CSF IL-10 concentration was dramatically decreased by the zanubrutinib monotherapy, which was related to the control of CNS lymphoma and demonstrates the significant anti-tumor activity of zanubrutinib (Figure 3). This evidence concerns the gene IL10 and primary central nervous system lymphoma.